Option chain shows key data for Petros Pharma's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Petros Pharma.

Petros Pharma (NASDAQ:PTPI) Stock, Option Chain

Petros Pharmaceuticals

Petros Pharmaceuticals Inc is a men's health pharmaceutical company. It focuses on therapeutics that promote medication adherence, tolerability, and preservation of male organic function. The company's operating segment includes Prescription Medications and Medical Devices. It generates maximum revenue from the Medical Devices segment. The Prescription Medications segment consists of operations related to vacuum erection devices, which are sold domestically and internationally.

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AEMD

APCX

CURE PHARMA HLDG CORP by CURE Pharmaceutical Holding Corp.

CURR

DALN

DSGN

ELAB

KULR

LITM

MESO

NVNI

PTPI

QNTM

SGMO

SLXN

VRAX

Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

Earnings

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

RZLV

SHLT

SSBK

TNXP

VSTE

Why Corvus Pharmaceuticals Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket

Amazon, Crowdstrike, Autodesk, Dell, And Tesla: Why These 5 Stocks Are On Investors' Radars Today

CANG

CELC

DBGI

EVGO

GRYP

LAES

MAMA

MITK

Merrill Lynch & Strategic Return Notes for Select 10 Index

NAYA

OPTX

PSBD

RVPH

SEDG

SIDU

WBUY

Why Mitek Systems Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Petros Pharmaceuticals, Inc. - Common Stock

Petros Pharmaceuticals Inc

PT CHANDRA ASRI PACIFIC by PT Chandra Asri Pacific Tbk

PT Chandra Asri Pacific Tbk

December 2024 Observations:
<ul>
<li>Supported by favorable move-in and move-out levels, December weighted average occupancy increased 100 basis points year-over-year, from 78.3% in 2023 to 79.3% in 2024.</li>
<li>Fourth quarter 2024 weighted average occupancy also increased 100 basis points compared to the prior year quarter.</li>
<li>Sequentially, fourth quarter 2024 weighted average occupancy increased 50 basis points compared to the third quarter, exceeding normal pre-pandemic seasonality for this period.</li>
<li>Fourth quarter 2024 move-in volume surpassed the prior year and exceeded the pre-pandemic average for this period by 8%.</li>
</ul>

Reported Earlier, Brookdale Senior Living Reports December 2024 Occupancy Increase To 79.3%, Up 100 Basis Points YoY

RKLB

Reported Earlier, Rocket Lab Expands NASA Partnership With Neutron Launch Services For VADR Payloads

"We are pleased to announce an approximately 7.5% increase to FSCO's monthly distribution," said&nbsp;Andrew Beckman, Head of FS Investments' Global Credit business and Portfolio Manager for FSCO. "Our new monthly distribution rate of&nbsp;$0.0645&nbsp;per share represents an increase of approximately 51.8% over the Fund's distribution at the time of the listing in November of 2022, and the second increase over the last twelve months. The Fund's dynamic credit strategy investing across both public and private markets, coupled with our experienced investment team and attractive portfolio, position us well to provide an attractive yield for our shareholders and deliver strong total returns."
The current annualized distribution rate equates to an annualized distribution yield1&nbsp;of 10.1% and 10.6%, respectively, based on the Fund's net asset value (NAV) and market price as of December 31, 2024. The monthly distribution has been fully covered by the Fund's net investment income throughout 2024, and the Fund has generated an estimated total return on NAV of 14.24% and 34.7% on market price year-to-date through December 31, 2024.

Dividends

FSCO

Reported Earlier, FSCO Declares Monthly Distribution Of $0.0645 For January 2025, Reflecting A 7.5% Increase

Starbucks Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) is once again embroiled in labor disputes as its union has filed 34 new complaints&nbsp;with the National Labor Relations&nbsp;Board, marking a resurgence in tensions.
What Happened: The complaints, lodged by Starbucks Workers United, accuse the company of breaching federal labor laws, Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-01-10/starbucks-union-files-34-federal-complaints-signaling-renewed-hostilities">reported</a> on Friday
Allegations include targeting and dismissing employees for their union activities across 16 states. These actions follow a previous complaint filed on Dec. 20, accusing Starbucks of unfair negotiation practices.
Starbucks has dismissed the allegations as unfounded. 
&#8220;Taking&nbsp;time to file such claims&nbsp;is a tactic that brings&nbsp;distraction from the progress we&nbsp;could be making,&#8221; said company spokesperson Phil Gee in an emailed statement to Bloomberg. The NLRB will investigate these cases, and if found credible, they could proceed to agency judges.
The recent filings and strikes reflect ongoing labor disputes reminiscent of those in 2022 and 2023. Despite earlier efforts to resolve differences, talks broke down over pay issues, with the union accusing Starbucks of inadequate economic proposals.
Why It Matters: The recent complaints come on the heels of a significant labor strike during the holiday season. Starbucks workers <a href="https://www.benzinga.com/markets/equities/24/12/42640897/starbucks-strike-expands-to-more-us-cities-as-wage-negotiations-stall-during-busy-holiday-season">expanded their strike </a>to more U.S. cities as wage negotiations stalled. The strike, which began in major cities like Los Angeles, Chicago, and Seattle, eventually spread to New Jersey, New York, Philadelphia, and St. Louis. Workers United demanded substantial wage increases, which Starbucks deemed &#8220;unsustainable.&#8221;
Further intensifying the situation, over <a href="https://www.benzinga.com/news/24/12/42666501/starbucks-faces-major-strike-on-christmas-eve-300-locations-affected-as-5000-workers-walk-out">300 Starbucks locations</a> were affected by a strike on Christmas Eve, involving more than 5,000 workers. Unresolved disputes over wages, staffing, and schedules were at the core of the strike. With over 60 stores in major cities shut, the ongoing labor unrest highlights the deepening rift between Starbucks and its employees.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41478176/trump-media-mcdonalds-starbucks-philip-morris-and-tesla-why-these-5-stocks-are-on-investors-rada">Trump Media, Mcdonald&#8217;s, Starbucks, Philip Morris, And Tesla: Why These 5 Stocks Are On Investors&#8217; Radars Today</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Equities

General

SBUX

Starbucks Faces 34 New Union Complaints Amid Rising Tensions with Workers

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the <a href="https://www.globenewswire.com/Tracker?data=e3VsfxUbo-yZkKbrkPomsnLaoTxIULLUg8SGhzOUD3LZsVTnph0ap0ONCJT2yjG7Ru0ZDySSBGuiWyqIAOc679R1p4wjBMWp_qS-Qp2fX0WOqAyNh_GjNdsmfUCND9P7KafrTRXVKCgUhT3KL4uAZSO2gzMV4eblYoFnZYFyHHH79mO2VhGLi_cscUCakM-H">MyRisk&#xAE; with RiskScore&#xAE; Hereditary Cancer Test</a>, the first and industry-leading hereditary cancer test and polygenic risk prediction test for all ancestries. She will promote the importance of collecting a detailed family health history for cancer and understanding the associated cancer risks.
 &nbsp;

MYGN

Reported Earlier, Myriad Genetics Signs Agreement With Hannah Storm To Highlight Importance Of Knowing Family Cancer Risk

The new contract will incorporate catering and retail services; village, mine and port site cleaning services; facilities maintenance; and the provision of health and wellbeing solutions.
It is anticipated the six-year contract will generate approximately A$1.4B in revenues over the 2025-2030 contract period. Civeo has been operating the four additional villages under a Limited Notice To Proceed agreement since the second quarter of 2024.

CVEO

Reported Earlier, Civeo Renews A$1.4B Integrated Services Contract With Broader Scope In Australia

Reported Earlier, Wheaton Precious Metals Announces CFO Transition: Vincent Lau To Succeed Gary Brown In March 2025

<ul>
<li>Fourth quarter consolidated production was 80,438 ounces of gold and 14.5 million pounds of copper, representing the highest gold and copper production quarter of 2024, resulting in a 2% and 20% increase over the prior-year period, and 3% and 15% increase over the third quarter of 2024, respectively.</li>
<li>New Afton fourth quarter production was 19,652 ounces of gold and 14.5 million pounds of copper, an increase of 19% gold production and 15% copper production over the third quarter. The B3 cave performed as planned, and C-Zone ore production is ramping up as planned following commercial production and crusher commissioning early in the fourth quarter. Gold production beat the top end of the original 2024 guidance, with copper production achieving the midpoint.</li>
<li>Rainy River fourth quarter production was 60,786 ounces of gold. Fourth quarter operations were adversely impacted by unexpected mechanical down-time on the crushing and conveying system in December, leading to lower than expected throughput. As a result, fourth quarter production, specifically December production, was below plan, leading to gold production slightly below the updated 2024 guidance range.</li>
<li>2024 consolidated gold production of 298,303 ounces of gold was slightly below the updated consolidated guidance range of 300,000 to 310,000 ounces, while 54.0 million pounds of copper achieved the midpoint of initial copper production guidance range outlined at the start of 2024. Consolidated all-in sustaining costs3 are expected to be at the low end of the guidance range of $1,240 to $1,340 per gold ounce sold on a by-product basis.</li>
</ul>

Reported Earlier, New Gold Reported Q4 2024 Gold Production Of 80,438 Ounces (+2% YoY) And 14.5M Pounds (+20% YoY) Of Copper

Theratechnologies Inc. announced that a shortage of EGRIFTA SV&#xAE; (tesamorelin for injection) will occur at the patient level in mid-January 2025, following a voluntary shutdown of the contract manufacturing facility in 2024. While the Company is aware of remaining inventory of EGRIFTA SV&#xAE; in certain pharmacies throughout the United States, several pharmacies have reported stockouts.

THTX

Reported Earlier, Theratechnologies Alerts Patients to EGRIFTA SV Supply Shortage Amid Manufacturing Shutdown

Nuveen California Dividend Advantage Municipal Fund 2

Reported Earlier, NOVONIX And Harper Expand Collaboration With Licensing Agreement For Graphitization Furnace Technology

Through this collaboration, Zai Lab further expands its global oncology pipeline with another potential first-in-class ADC targeting multiple solid tumors and addressing significant unmet medical needs. ZL-6201 has demonstrated encouraging preclinical data with an IND expected to be filed in 2025.

ZLAB

Reported Earlier, Zai Lab Expands Oncology Pipeline With MediLink Collaboration For Novel LRRC15 ADC ZL-6201

Collaboration expected to provide technology and capabilities to deliver comprehensive AI data center solutions and services to expanded geographic regions

HXSCF

Penguin Solutions, Inc. - Ordinary Shares

PENG

Reported Earlier, Penguin Solutions Teams Up With SK Telecom And SK Hynix To Deliver Global AI Data Center Solutions

UK Biobank Pharma Proteomics Project aims to create a comprehensive map of disease-associated protein levels in the human body to advance biomarker discovery

Reported Earlier, Thermo Fisher's Olink Platform Chosen For UK Biobank Project Analyzing Protein Risk Factors For Disease

Prestigious Mayfair casino location expands Wynn's footprint in Europe and the Middle East ahead of Wynn Al Marjan Island opening in the UAE

WYNN

Reported Earlier, Wynn Resorts To Acquire Crown London Casino In Mayfair, Expanding Presence In Europe And The Middle East

Amylyx intends to use the net proceeds from this offering, together with existing cash, cash equivalents and marketable securities, to advance preparations for commercialization and pipeline programs, for working capital and for general corporate purposes

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

Reported Earlier, Amylyx Pharmaceuticals Launches Public Offering Of Common Stock, Aims To Advance Pipeline And Operations

Reported Earlier, GlocalMe Highlights Updated Brand Identity And New Connectivity Devices At CES 2025

Shoals Technologies Group, Inc. ("Shoals") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHLS#NASDAQ">SHLS</a>), a global leader in electrical balance of system ("EBOS") solutions for the energy transition market, announced today that it has filed a new patent infringement complaint with the U.S. International Trade Commission ("ITC") against Voltage, LLC and related foreign entity. This complaint cites two new patents (‘375 and ‘376 Patents) that cover Shoals' Big Lead Assembly ("BLA") solutions.

SHLS

Reported Earlier, Shoals Technologies Submits Another Patent Infringement Complaint Against Voltage, LLC To The ITC

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) has expressed strong disapproval of the Biden administration&#8217;s anticipated chip export restrictions. The proposed regulations aim to limit the global sale of U.S. artificial intelligence chips.
What Happened: The new rules, expected to be announced as soon as Friday, are designed to curb chip exports to most nations, with a focus on preventing advanced technology from reaching China and Russia. Ned Finkle, Nvidia's vice president of government affairs, criticized the policy, arguing it would not bolster national security but instead push the world towards alternative technologies, Bloomberg<a href="https://www.bloomberg.com/news/articles/2025-01-10/nvidia-slams-biden-for-trying-to-preempt-trump-with-chip-rules"> reported</a> on Wednesday.
Finkle contended that the policy, which includes a &#8220;country cap,&#8221; would affect mainstream computers globally. He highlighted that the technology in question is already common in gaming PCs and everyday data-center computers, questioning the logic behind the restrictions.
The proposed regulations would create three tiers of chip curbs, allowing some U.S. allies full access to American chips. However, most countries would face new limitations, including caps on computing power. 
"This last-minute Biden administration policy would be a legacy that will be criticized by U.S. industry and the global community," Finkle said. 
Why It Matters: The Biden administration&#8217;s proposed export restrictions are part of a broader strategy to concentrate artificial intelligence technology development with allies and on Washington's terms. Nvidia and other semiconductor companies are <a href="https://www.benzinga.com/25/01/42897081/nvidia-and-ai-chip-stocks-brace-for-impact-as-biden-administration-considers-new-china-export-ban-report">preparing for potential impacts</a> from these restrictions.
The Biden government is considering a fresh sanction on the export of AI chips used in data centers, both on a country and company basis, before the transition to the Republican government led by Donald Trump on Jan. 20. The proposed rules could enact three tiers of chip curbs, affecting the global semiconductor market and potentially altering the competitive landscape.
Read Also: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42901087/bidens-final-chip-curbs-set-to-shake-ai-markets-globally-10-etfs-to-watch-with-high-stakes-on-nvidia-amd">Biden&#8217;s Final Chip Curbs Set To Shake AI Markets: 10 ETFs With High Stakes In Nvidia, AMD</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Image via Shutterstock

NVDA

Nvidia Slams Biden's Country-Specific Chip Rules: 'Legacy That Will Be Criticized'

Elon Musk has requested the attorneys-general of California and Delaware to mandate an auction of a substantial portion of OpenAI&#8217;s stake.
What Happened: Musk&#8217;s legal representative, Marc Toberoff, reached out to the top legal officers of the states on behalf of major AI investors, advocating for an open bidding process, <a href="https://www.ft.com/content/596dddb3-0607-44b9-b565-9c0d62e49b9f">reported</a> Financial Times on Thursday.
However, OpenAI has no intention of conducting such an auction, the report noted, citing according to a source familiar with the company&#8217;s position.
See Also: <a href="https://www.benzinga.com/news/25/01/42904409/elon-musk-hosts-x-spaces-with-afds-alice-weidel-after-successfully-endorsing-trump-share-views-on-nuclear-power-and-future-of-europe-with-far-right-german-leader">Elon Musk Hosts X Spaces With Afd&#8217;s Alice Weidel After Successfully Endorsing Trump: Share Views On Nuclear Power And Future Of Europe With Far Right German Leader</a>
Musk&#8217;s legal team contends that an auction is essential to ensure the non-profit receives maximum value for its assets. Sources suggest that the non-profit&#8217;s stake in the proposed public benefit corporation could be worth billions.
The attorneys general have not yet responded to Musk&#8217;s request.
Subscribe to the <a href="https://bztechtrends.beehiiv.com/subscribe">Benzinga Tech Trends newsletter</a> to get all the latest tech developments delivered to your inbox.
Why It Matters: The dispute originates from OpenAI&#8217;s shift from a non-profit to a <a href="https://www.benzinga.com/24/12/42712683/openai-lays-out-its-for-profit-transition-plans-says-it-must-evolve-to-advance-its-agi-mission">for-profit entity</a>, a transition Musk has opposed. The Sam Altman-led company plans to become a public benefit corporation, requiring the non-profit to relinquish control over its operations.
Earlier, the &#8220;Godfather of AI,&#8221; Geoffrey Hinton, expressed <a href="https://www.benzinga.com/general/education/25/01/42778778/elon-musk-gets-support-from-godfather-of-ai-geoffrey-hinton-in-battle-against-openai">support for Musk&#8217;s stance</a>. Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) has also backed Musk, arguing that OpenAI should not convert assets developed under its <a href="https://www.benzinga.com/24/12/42495758/elon-musk-finds-an-unlikely-ally-in-mark-zuckerbergs-meta-in-his-fight-against-sam-altmans-openai">non-profit status for private gain</a>.
OpenAI&#8217;s valuation soared to $157 billion last year. The AI startup has received about $14 billion in investment from Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTF#NASDAQ">MSTF</a>).
Image via Wikimedia Commons
Check out more of Benzinga&#8217;s Consumer Tech coverage by <a href="https://www.benzinga.com/topic/consumer-tech">following this link</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/01/42900737/stephen-king-slams-elon-musks-h-1b-visa-stance-musk-thinks-smart-immigrants-can-stay-the-rest-of-you-washing-dishes-get-lost">Stephen King Slams Elon Musk's H-1B Visa Stance: ‘Musk Thinks Smart Immigrants Can Stay – The Rest of You Washing Dishes … Get Lost'</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.

Legal

Tech

Media

MSTF

Elon Musk Pushes California, Delaware Attorneys-General To Force OpenAI Stake Auction Amid Bitter Legal Battle With Sam Altman

Macro Economic Events

Econ #s

Economics

BBJP

WisdomTree Trust Japan Total Dividend Fund

Reported Earlier, Japan Household Spending (MoM) For November 0.4% Vs. -0.9% Est.; 2.9% Prior

Naz Rahman, an analyst from Maxim Group, maintained the Buy rating on Petros Pharmaceuticals (PTPI – Research Report). The associated price target ...

Buy Rating Justified for Petros Pharmaceuticals Amid AI Integration and Strategic OTC Expansion

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!



Moving stocks this morning are clinical trail updates, an earnings report, acquisition news and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Neo-Concept (NASDAQ:<a href="https://investorplace.com/stock-quotes/nci-stock-quote/">NCI</a>) stock is rocketing more than 60% alongside heavy pre-market trading.</li>



<li>Sify Technologies Limited &ndash; Rights&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/sifyr-stock-quote/">SIFYR</a>) shares are soaring over 29% <a href="https://www.nasdaq.com/articles/sify-technologies-sets-ads-rights-delisting-date">before their delisting next week</a>.</li>



<li>Longeveron (NASDAQ:<a href="https://investorplace.com/stock-quotes/lgvn-stock-quote/">LGVN</a>) stock is surging more than 28% <a href="https://investorplace.com/2024/06/why-is-longeveron-lgvn-stock-up-120-today/">with clinical trial news</a>.</li>



<li>Fangdd Network (NASDAQ:<a href="https://investorplace.com/stock-quotes/duo-stock-quote/">DUO</a>) shares are gaining over 24% with strong early morning trading.</li>



<li>Nxu (NASDAQ:<a href="https://investorplace.com/stock-quotes/nxu-stock-quote/">NXU</a>) stock is increasing more than 17% on heavy early morning trading.</li>



<li>Sequans Communications (NYSE:<a href="https://investorplace.com/stock-quotes/sqns-stock-quote/">SQNS</a>) shares are rising over 16% today.</li>



<li>Broadcom (NASDAQ:<a href="https://investorplace.com/stock-quotes/avgo-stock-quote/">AVGO</a>) stock is heading 13% higher on <a href="https://www.barrons.com/articles/broadcom-stock-split-earnings-0c75392f">Q2 earnings and stock split plans</a>.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are climbing more than 11% without any clear news today.</li>



<li>CaliberCos (NASDAQ:<a href="https://investorplace.com/stock-quotes/cwd-stock-quote/">CWD</a>) stock is jumping over 11% this morning.</li>



<li>Roma Green Finance (NASDAQ:<a href="https://investorplace.com/stock-quotes/roma-stock-quote/">ROMA</a>) shares are up more than 10% </li>
</ol><h2>10 Top Losers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is crashing over 52% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318390446&amp;type=PDF&amp;symbol=IONM&amp;cdn=e3ce016dbdad608e6e12f639f088590d&amp;companyName=Assure+Holdings+Corp.&amp;formType=425&amp;formDescription=Prospectuses+and+communications%2C+business+combinations&amp;dateFiled=2024-06-12">terminating a merger agreement</a>.</li>



<li>DDC Enterprise (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ddc-stock-quote/">DDC</a>) shares are plummeting more than 28% after <a href="https://www.marketwatch.com/story/ddc-enterprise-shares-surge-after-purchase-of-omsom-2ae3de86?mod=markets">rallying yesterday on an acquisition</a>.</li>



<li>Cara Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/cara-stock-quote/">CARA</a>) stock is diving over 20% alongside <a href="https://www.nasdaq.com/press-release/cara-therapeutics-announces-outcome-part-kourage-1-study-evaluating-oral">clinical trial results</a>.</li>



<li>Petros Pharma (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) shares are tumbling more than 18% on Thursday morning.</li>



<li>PainReform (NASDAQ:<a href="https://investorplace.com/stock-quotes/prfx-stock-quote/">PRFX</a>) stock is taking an over 16% beating this morning.</li>



<li>J.Jill (NYSE:<a href="https://investorplace.com/stock-quotes/jill-stock-quote/">JILL</a>) shares are falling more than 16% after <a href="https://www.nasdaq.com/press-release/jjill-announces-pricing-public-offering-common-stock-2024-06-12">pricing a public offering</a>.</li>



<li>EpicQuest Education (NASDAQ:<a href="https://investorplace.com/stock-quotes/eeiq-stock-quote/">EEIQ</a>) stock is dropping over 16% this morning.</li>



<li>Expion360 (NASDAQ:<a href="https://investorplace.com/stock-quotes/xpon-stock-quote/">XPON</a>) shares are decreasing more than 14% today.</li>



<li>KWESST Micro Systems (NASDAQ:<a href="https://investorplace.com/stock-quotes/kwe-stock-quote/">KWE</a>) stock is declining over 12% as it <a href="https://investorplace.com/2024/06/why-is-kwesst-micro-systems-kwe-stock-up-121-today/">comes off a recent rally</a>.</li>



<li>VS Media (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsme-stock-quote/">VSME</a>) shares close out our pre-market stock movers down more than 12%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-13th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Petros Pharmaceuticals (PTPI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Naz Rahma...

Buy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic Advancements

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Petros Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/ptpi-stock-quote/">PTPI</a>) just reported results for the second quarter of 2024.<ul><li>Petros Pharmaceuticals reported earnings per share of -37 cents. This was above the analyst estimate for EPS of -77 cents.</li><li>The company reported revenue of $1.42 million.</li><li>This was 1.50% better than the analyst estimate for revenue of $1.40 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ptpi-stock-earnings-petros-pharmaceuticals-for-q2-of-2024/">PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

PTPI Stock Earnings: Petros Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024

Maxim Group analyst Naz Rahman reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) yesterday. The company's shares closed ye...

Maxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)

Analyst Naz Rahman from Maxim Group reiterated a Buy rating on Petros Pharmaceuticals (PTPI – Research Report) and decreased the price target to $1...

Positive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals' OTC Stendra

The latest update is out from Petros Pharmaceuticals ( ($PTPI) ). John Shulman and Greg Bradley, both members of the board of directors at Petros P...

Board Reshuffle at Petros Pharmaceuticals Following Resignations

An update from Petros Pharmaceuticals ( ($PTPI) ) is now available. Petros Pharmaceuticals has amended its employment agreement with President Fady...

Petros Pharmaceuticals Amends President's Employment Terms

Petros Pharmaceuticals (PTPI) announces a shift in its corporate strategy to focus on the development of its proprietary technology platform as a p...

Petros to shift focus to development of tech as Rx-to-OTC switch solution

Petros Pharmaceuticals (PTPI) announces its conducive position in connection with the recently issued final rule, "Nonprescription Drug Product wit...

Petros announces 'conducive position' with newly approved FDA OTC final rules

AVGO

CARA

EEIQ

IONM

JILL

LGVN

PRFX

ROMA

SIFYR

SQNS

VSME

XPON

Biotech

Press Releases

Petros Pharmaceuticals Launches U.S. Distribution of Prescription ED Medication STENDRA Through Recently Announced Collaboration With Lemonaid Health, a Subsidiary of 23andMe

Petros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRA

Petros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC Switch

Petros Pharmaceuticals' STENDRA(R) (avanafil) Pivotal Consumer Self-Selection Study for Over-the-Counter Access Demonstrates Statistical Significance

Petros Pharmaceuticals' Pivotal Statistically Significant Self Selection Study Shows Stronger Results with Proprietary Technology Application as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Events

Petros Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Petros Pharmaceuticals Featured in "New Era of Healthcare, AI, Data and Consumer Empowerment"

Petros Pharmaceuticals Strategically Positioned to Benefit as Technology Leader from Newly Approved FDA OTC Final Rules

Comments

Petros Pharma

Petros Pharma (PTPI) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga